register

News & Trends - MedTech & Diagnostics

J&J led largest medtech M&A in 2022

Health Industry Hub | January 20, 2023 |

MedTech News: Johnson & Johnson’s $17bn acquisition accounted for 42% of medtech M&A spend last year.

Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment. The acquisition adds heart recovery solutions to complement the company’s Biosense Webster electrophysiology business, supporting the company’s expansion in high-growth markets. 

The size and the target of this deal caught the company “off guard”. However, the organisation believes Abiomed is a “high-quality target and fits JNJ’s businesses and company culture well”.

J&J said the acquisition is expected to be slightly dilutive to earnings per share in the first year, then adding $0.05 per share in 2024 and increasingly accretive thereafter.

Interestingly, J&J’s Abiomed takeout was the second-largest in the overall life sciences sector, behind only Amgen’s $28bn acquisition of Horizon, which specialises in medicines for rare and autoimmune diseases.

In comparison, the largest deal Medtronic closed last year involved the sinusitis specialist Intersect ENT at $1.2bn.

One deal is already on the books for 2023 with Thermo Fisher’s £2.3bn ($2.8bn) purchase of The Binding Site earlier this month.

Other big groups that have expressed an interest in buying include Abbott and Medtronic, although they are mostly focused on sub-$1bn tuck-in deals.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.